79 unknown. 79 Phase 2, 13 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 79 | Unknown 79 |
| Phase 1 | 13 | Unknown 13 |
| Phase 3 | 1 | Unknown 1 |
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer Quercetin, Dasatinib, Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum - Triple-negative Breast Cancer | Phase 2 | Unknown | Fudan University | 10 | 2024-05-20 | 2024-07-08 |
| Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial Xiaopi granules, Xiaopi decoction, Placebo - Triple Negative Breast Neoplasms | Phase 2 | Unknown | Zhiyu Wang | 90 | 2023-11-25 | 2023-12-01 |
| PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors CVL218 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Fujian Cancer Hospital | 96 | 2023-10-10 | 2023-10-12 |
| A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer AT regimen, Tislelizumab, Anlotinib - Triple-negative Breast Cancer | Phase 2 | Unknown | Sichuan Provincial People's Hospital | 32 | 2023-09-15 | 2024-01-22 |
| T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients Trastuzumab Deruxtecan - Triple-Negative Breast Cancer | Phase 2 | Unknown | Fudan University | 69 | 2023-08-01 | 2023-07-19 |
| A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies ILB-2109, Toripalimab - Head and Neck Cancer, Cervical Cancer | Phase 1 / Phase 2 | Unknown | Innolake Biopharm | 200 | 2023-07-25 | 2024-05-21 |
| Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC Trilaciclib - Triple Negative Breast Cancer | Phase 2 | Unknown | QIAO LI | 50 | 2023-07-03 | 2025-05-02 |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2) A1:SG with SHR3680, A2:SG, B1:SG with SHR1210 - TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 125 | 2023-07-01 | 2023-07-03 |
| CTS2190 Phase I /II Clinical Study in Patients CTS2190 capsules - Solid Tumors, Pancreatic Cancer | Phase 1 / Phase 2 | Unknown | CytosinLab Therapeutics Co., Ltd. | 224 | 2023-06-26 | 2024-08-23 |
| Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer Doxorubicin, Cyclophosphamide, Paclitaxel - Triple Negative Breast Cancer | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 82 | 2023-06-01 | 2023-05-25 |
| Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B) - Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Unknown | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 145 | 2023-05-15 | 2023-05-18 |
| Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide - TNBC - Triple-Negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2023-04-08 | 2023-04-28 |
| Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer Surufatinib, Tislelizumab - Metastatic Triple-negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Huihua Xiong | 45 | 2023-04-01 | 2023-04-06 |
| A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. Camrelizumab plus Famitinib with/without nab-Palitaxel - Triple-Negative Breast Cancer | Phase 2 | Unknown | Fudan University | 46 | 2023-03-01 | 2023-02-28 |
| A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs Anti-PD-1 monoclonal antibody, VEGFR2 Tyrosine Kinase Inhibitor - Breast Cancer, Triple-Negative Breast Cancer | Phase 2 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 58 | 2022-12-01 | 2023-04-12 |
| Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients Cisplatin, Nab-paclitaxel, Pembrolizumab - Triple Negative Breast Cancer | Phase 2 | Unknown | Fudan University | 136 | 2022-09-07 | 2023-09-28 |
| To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer Toripalimab, Epirubicin, High Intensity Focused Ultrasoun - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 20 | 2022-09-01 | 2022-08-08 |
| Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency Niraparib - Homologous Recombination Deficiency, Triple Negative Breast Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 50 | 2022-09-01 | 2022-07-18 |
| A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy - Colorectal Cancer, Triple Negative Breast Cancer | Phase 2 | Unknown | OncXerna Theraputics, Inc. | 180 | 2022-08-05 | 2023-01-31 |
| Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial Capecitabine, Tucidinostat - Triple Negative Breast Cancer | Phase 2 | Unknown | wang shusen | 126 | 2022-08-01 | 2022-11-04 |
Showing 20 of 79. Sign in to see all of them.
Breast Neoplasms (22) · Carcinoma, Non-Small-Cell Lung (4) · Stomach Neoplasms (4) · Carcinoma, Renal Cell (3) · Neoplasm Metastasis (3) · Carcinoma, Transitional Cell (2) · Melanoma (2) · Ovarian Neoplasms (2) · Pathologic Complete Response (2) · Sarcoma (2) · Uterine Cervical Neoplasms (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms, Male (1) · Carcinoma (1)
Breast Diseases (79) · Skin Diseases (79) · Skin and Connective Tissue Diseases (79) · Neoplasms (78) · Neoplasms by Site (78) · Breast Neoplasms (57) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Neoplasms by Histologic Type (5) · Neoplasms, Glandular and Epithelial (5) · Urogenital Diseases (5)
Carboplatin (12) · camrelizumab (12) · Capecitabine (10) · 130-nm albumin-bound paclitaxel (9) · eribulin (7) · pembrolizumab (7) · Cisplatin (6) · Cyclophosphamide (6) · Gemcitabine (6) · Epirubicin (5) · Paclitaxel (5) · apatinib (5) · Bevacizumab (4) · atezolizumab (4) · toripalimab (4)
Fudan University (18) · Chinese Academy of Medical Sciences (5) · The First Affiliated Hospital with Nanjing Medical University (3) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (2) · Northwestern University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Abbisko Therapeutics Co, Ltd (1) · Aiping Shi (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Beijing 302 Hospital (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Leon Berard (1) · Consorzio Oncotech (1) · CytosinLab Therapeutics Co., Ltd. (1)
China (45) · United States (9) · Italy (3) · Australia (2) · France (2) · United Kingdom (2) · Bangladesh (1) · Denmark (1) · Malaysia (1) · South Korea (1) · Taiwan (1)
Aiping Shi, PhD (1) · Alberto Zambelli, MD (1) · Andrea Botticelli, MD (1) · Anette R Kodahl, MD, PhD (1) · Binghe XU, MD, PHD (1) · Binghe Xu (1) · Bridget O'Keeffe (1) · Carla Strina, MD (1) · Chiun-Sheng Huang, PhD (1) · Claudio Vernieri, M.D. PhD (1) · Feng Chi, PhD, RN (1) · Filippo de Braud, Professor (1) · Gregory A Vidal, MD.,PhD (1) · Gwo Fuang Ho, FRCR (1) · Hong MD Liu (1)
PMID 19299237, PMID 24529560, PMID 25092775, PMID 27872127, PMID 16011702, PMID 16077072, PMID 17438091, PMID 17641361, PMID 18258986, PMID 19097774, PMID 19487376, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20586616, PMID 21633166, PMID 21865043, PMID 22323820, PMID 24399079, PMID 25349301, PMID 25585328, PMID 25648299, PMID 26006067, PMID 26056183, PMID 26316884, PMID 26438237, PMID 27282289, PMID 27324108, PMID 27713176, PMID 28302091, PMID 28564564, PMID 29501363, PMID 29577076, PMID 29620997, PMID 29660596, PMID 29713086, PMID 29846104, PMID 29846122, PMID 29873695, PMID 29878040, PMID 30061361, PMID 30100160, PMID 30207593, PMID 30345906, PMID 30479698, PMID 32060053, PMID 32101663, PMID 32393788, PMID 32448335, PMID 32669709
2014 (1), 2016 (1), 2017 (1), 2019 (1), P30CA060553 (1)